Related references
Note: Only part of the references are listed.Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate
Stephen M. Stahl
CNS SPECTRUMS (2018)
Impulse control disorders in Parkinson's disease
Ana Marques et al.
JOURNAL OF NEURAL TRANSMISSION (2018)
Chronic cannabidiol exposure promotes functional impairment in sexual behavior and fertility of male mice
Renata K. Carvalho et al.
REPRODUCTIVE TOXICOLOGY (2018)
Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review
Stanley N. Caroff et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors
Andreza B. Sonego et al.
BRAIN BEHAVIOR AND IMMUNITY (2018)
The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study
Stewart A. Factor et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders
Thierry Q. Mentzel et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2017)
Clinical management of tardive dyskinesia: Five steps to success
Leslie Citrome
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia
Ashleigh L. Osborne et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2017)
Successful Treatment of Severe Tardive Dyskinesia with Valbenazine, Including a Patient's Perspective
Richard C. Josiassen et al.
AMERICAN JOURNAL OF CASE REPORTS (2017)
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders
Jonathan L. C. Lee et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice
Andreza B. Sonego et al.
BEHAVIOURAL BRAIN RESEARCH (2016)
Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes
Christian Lehmann et al.
CLINICAL HEMORHEOLOGY AND MICROCIRCULATION (2016)
Tetrabenazine: Spotlight on Drug Review
Navneet Kaur et al.
ANNALS OF NEUROSCIENCES (2016)
Cannabidiol as a Potential Treatment for Anxiety Disorders
Esther M. Blessing et al.
NEUROTHERAPEUTICS (2015)
Molecular Targets of Cannabidiol in Neurological Disorders
Clementino Ibeas Bih et al.
NEUROTHERAPEUTICS (2015)
Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio)
Luiza Reali Nazario et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2015)
Schizophrenia: a tale of two critical periods for prefrontal cortical development
L. D. Selemon et al.
TRANSLATIONAL PSYCHIATRY (2015)
Drug models of schizophrenia
Hannah Steeds et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2015)
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats
Jivago Roepke et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2014)
Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies
Josh Lister et al.
PSYCHOPHARMACOLOGY (2014)
Cognition impairment in schizophrenia patients with tardive dyskinesia: Association with plasma superoxide dismutase activity
Jing Qin Wu et al.
SCHIZOPHRENIA RESEARCH (2014)
Effects of cannabidiol on the function of α7-nicotinic acetylcholine receptors
Mohamed Mahgoub et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2013)
COX-2 and PPAR-γ Confer Cannabidiol-Induced Apoptosis of Human Lung Cancer Cells
Robert Ramer et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors
M. Mecha et al.
NEUROBIOLOGY OF DISEASE (2013)
Endocannabinoid system and mood disorders: Priming a target for new therapies
Vincenzo Micale et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Antioxidants as potential therapeutics for neuropsychiatric disorders
Chirayu D. Pandya et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Oxidative stress and therapeutic implications in psychiatric disorders
Xiang Yang Zhang et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence
Chul-Hyun Cho et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice
Felipe V. Gomes et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Valeria Almeida et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2013)
Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death
N. Rimmerman et al.
CELL DEATH & DISEASE (2013)
Relevance of animal models to human tardive dyskinesia
Pierre J. Blanchet et al.
BEHAVIORAL AND BRAIN FUNCTIONS (2012)
Ameliorative effect of yokukansan on vacuous chewing movement in haloperidol-induced rat tardive dyskinesia model and involvement of glutamatergic system
Kyoji Sekiguchi et al.
BRAIN RESEARCH BULLETIN (2012)
Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2012)
Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Peter Kovacic et al.
Current Neuropharmacology (2012)
Antipsychotic Profile of Cannabidiol and Rimonabant in an Animal Model of Emotional Context Processing in Schizophrenia
Raquel Levin et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis
James T. Teo et al.
MOVEMENT DISORDERS (2012)
Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice
J. J. Crowley et al.
PHARMACOGENOMICS JOURNAL (2012)
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
F. M. Leweke et al.
TRANSLATIONAL PSYCHIATRY (2012)
Tetrabenazine for the Treatment of Tardive Dyskinesia
Jonathan G. Leung et al.
ANNALS OF PHARMACOTHERAPY (2011)
Impulse control disorders in Parkinson's disease: recent advances
Valerie Voon et al.
CURRENT OPINION IN NEUROLOGY (2011)
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress
George W. Booz
FREE RADICAL BIOLOGY AND MEDICINE (2011)
Selective Inhibition of Striatal Fast-Spiking Interneurons Causes Dyskinesias
Aryn H. Gittis et al.
JOURNAL OF NEUROSCIENCE (2011)
Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania
Samira S. Valvassori et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Cannabidiol decreases body weight gain in rats: Involvement of CB2 receptors
Bogna Ignatowska-Jankowska et al.
NEUROSCIENCE LETTERS (2011)
Tardive dyskinesia and withdrawal emergent syndrome in children
Nicte I. Mejia et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2010)
Anxiety Disorders in Parkinson's Disease: Prevalence and Risk Factors
Nadeeka N. W. Dissanayaka et al.
MOVEMENT DISORDERS (2010)
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Sven Geisler et al.
NATURE CELL BIOLOGY (2010)
Oxidative stress in tardive dyskinesia: Genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes
Clement C. Zai et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2010)
THE KINETIC ISOTOPE EFFECT IN THE SEARCH FOR DEUTERATED DRUGS
Liming Shao et al.
DRUG NEWS & PERSPECTIVES (2010)
Glutamate Dysfunction in People with Prodromal Symptoms of Psychosis: Relationship to Gray Matter Volume
James M. Stone et al.
BIOLOGICAL PSYCHIATRY (2009)
Time-dependent vascular actions of cannabidiol in the rat aorta
Saoirse E. O'Sullivan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Cannabis and anxiety: a critical review of the evidence
Jose Alexandre Crippa et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2009)
Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats
Santhrani Thaakur et al.
JOURNAL OF NEURAL TRANSMISSION (2009)
Cannabidiol for the treatment of psychosis in Parkinson's disease
A. W. Zuardi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
Δ9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
Matthijs G. Bossong et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Inhibition of recombinant human T-type calcium channels by Δ9-Tetrahydrocannabinol and cannabidiol
Hamish Redmond Ross et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes
Guy Chouinard et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2008)
Course of recovery of cognitive impairment in patients with schizophrenia: A randomised double-blind study comparing sertindole and haloperidol
B. Gallhofer et al.
PHARMACOPSYCHIATRY (2007)
Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain
Anilkumar Pillai et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2007)
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Bhomraj Thanvi et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in β-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement
Giuseppe Esposito et al.
NEUROSCIENCE LETTERS (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Brain areas involved in spatial working memory
Marieke van Asselen et al.
NEUROPSYCHOLOGIA (2006)
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia
HC Margolese et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2005)
Atypical antipsychotics and parkinsonism
PA Rochon et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Agonistic properties of cannabidiol at 5-HT1a receptors
EB Russo et al.
NEUROCHEMICAL RESEARCH (2005)
5-HT2 receptors and anxiety
M Bourin et al.
DRUG DEVELOPMENT RESEARCH (2005)
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
FA Moreira et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Nicotine-antipsychotic drug interactions and attentional performance in female rats
AH Rezvani et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients
S Janno et al.
AMERICAN JOURNAL OF PSYCHIATRY (2004)
Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment
DR Evans et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2003)
Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia
ZJ Zhang et al.
PSYCHIATRIC GENETICS (2003)
Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain
V Parikh et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2003)
Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats
N Addy et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms
PS Naidu et al.
BRITISH JOURNAL OF PHARMACOLOGY (2002)
Atypical antipsychotics: Mechanism of action
P Seeman
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2002)
Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats
PS Naidu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
Cannabis induced dopamine release: an in-vivo SPECT study
LNP Voruganti et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2001)
Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements
PS Naidu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2001)
μ- and δ-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease
B Henry et al.
EXPERIMENTAL NEUROLOGY (2001)
Pharmacogenetic assessment of antipsychotic-induced movement disorders:: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes
V Özdemir et al.
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS (2001)
The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis
AM Malfait et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
